Elisa Oricchio

Elisa Oricchio was born in 1979[1] and grew up in Cilento, Italy.[2] She earned a bachelor's degree and went on to[3] attain a master's degree in biology from Sapienza University of Rome.[4] In 2008, she earned her PhD in Medical Microbiology and Immunology from the University of Rome Tor Vergata. Oricchio moved to the United States almost immediately to begin her post-doctorate research at Memorial Sloan Kettering Cancer Center in New York City. In her research, she identified in 2011 that tumor cells treated with pure EphA7, an anti-tumor protein, died, which was a significant discovery in a rarely researched field.[5] Her discovery was awarded with a grant from Sloan Kettering and a Fellowship from the Lymphoma Research Foundation[4] to make further studies of follicular lymphoma.[5] In addition to the research funds, she received the Lorini Foundation Award on 7 May 2012 in Milan, Italy[6] and the Blavatnik Award for Young Scientists in New York City, the same year.[4]

In 2012, her research identified that nearly 70% of patients with follicular lymphoma have lost the EphA7 receptor[5] and she was experimenting with methods of reintroducing the protein into the cells.[4] Because there has been no cure success with traditional chemotherapies,[7] Oricchio's work has repeatedly been funded. She was awarded a second Fellowship from the Leukemia and Lymphoma Society[4] and a grant from the US National Institutes of Health.[7] In 2013, she was awarded with a plaque from the town of Vallo della Lucania in her home region of Italy for her research,[2][8] which was successful in developing a mouse model.[9] In 2014, she was hired by the Swiss Federal Institute of Technology as a researcher and to support creation of the new Swiss Cancer Center in Lausanne at the Lausanne University Hospital.[1] The Swiss Institute for Experimental Cancer Research created an endowed chair in Translational Oncology for Oricchio and effective 1 November 2014, she became a tenured assistant professor at the École Polytechnique Fédérale de Lausanne, School of Life Sciences.[9] In September 2021, she was promoted associate professor.[10]

• Oricchio, Elisa; Saladino, Chiara; Iacovelli, Stefano; Soddu, Silvia; Cundari, Enrico (21 January 2006). "ATM is activated by default in mitosis, localizes at centrosomes and monitors mitotic spindle integrity". Cell Cycle. Rome, Italy: Institute of Biology and Molecular Pathology, National Research Council. 5 (1): 88–92. doi:10.4161/cc.5.1.2269. PMID 16319535.
• Bonaccorsi, Irene; Altieri, Fabio; Sciamanna, Ilaria; Oricchio, Elisa; Grillo, Caterina; et al. (20 May 2008). "Endogenous reverse transcriptase as a mediator of ursolic acid's anti-proliferative and differentiating effects in human cancer cell lines". Cancer Letters. Messina, Italy: School of Pharmacy, University of Messina. 263 (1): 130–139. doi:10.1016/j.canlet.2007.12.026. PMID 18282657.
• Mavrakis, Konstantinos J; Wolfe, Andrew L; Oricchio, Elisa; Palomero, Teresa; et al. (28 April 2010). "Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia". Nature Cell Biology. New York, New York: Nature Publishing Group. 12 (4): 372–379. doi:10.1038/ncb2037. PMC 2989719. PMID 20190740.
• Oricchio, Elisa; Wolfe, Andrew L; Schatz, Jonathan H; Mavrakis, Konstantinos J; et al. (November–December 2010). "Mouse models of cancer as biological filters for complex genomic data". Disease Models & Mechanisms. Cambridge, UK: The Company of Biologists. 3 (11–12): 701–704. doi:10.1242/dmm.006296. PMC 2965398. PMID 20876355.
• Oricchio, Elisa; Nanjangud, Gouri; Wolfe, Andrew L; Schatz, Jonathan H; et al. (October 2011). "The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma". Cell. Cambridge, Massachusetts: Elsevier Inc. 147 (3): 554–564. doi:10.1016/j.cell.2011.09.035. PMC 3208379. PMID 22036564.
• Oricchio, Elisa; Wendel, Hans-Guido (15 March 2012). "Mining the cancer genome uncovers therapeutic activity of EphA7 against lymphoma". Cell Cycle. New York, New York: Taylor & Francis. 11 (6): 1076–1080. doi:10.4161/cc.11.6.19451. PMC 3335915. PMID 22356769.
• Oricchio, Elisa; Wendel, Hans-Guido (July 2013). "Functional genomics lead to new therapies in follicular lymphoma". Annals of the New York Academy of Sciences. New York, New York: New York Academy of Sciences. 1293 (1): 18–24. Bibcode:2013NYASA1293...18O. doi:10.1111/nyas.12120. PMC 3987118. PMID 23676193.
• Oricchio, Elisa; Ciriello, Giovanni; Jiang, Man; Boice, Michael H; et al. (June 2014). "Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy". Journal of Experimental Medicine. New York, New York: The Rockefeller University Press. 211 (7): 1379–1391. doi:10.1084/jem.20132120. PMC 4076578. PMID 24913233.

• WorldCat Publications
• PubFacts Scientific Research Publications List